{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:20:47Z","timestamp":1789204847172,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007185","name":"University of California, Los Angeles","doi-asserted-by":"publisher","award":["20173930"],"award-info":[{"award-number":["20173930"]}],"id":[{"id":"10.13039\/100007185","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.neurot.2025.e00610","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T15:47:52Z","timestamp":1747756072000},"page":"e00610","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Discovery of an APP-selective BACE1 inhibitor for Alzheimer's disease"],"prefix":"10.1016","volume":"22","author":[{"given":"Jesus","family":"Campagna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Jagodzinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongwook","family":"Wi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunni","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitaker","family":"Cohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Jun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Elias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar","family":"Padder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Descamps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Peters-Libeu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Gorostiza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Poksay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Spilman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale","family":"Bredesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varghese","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5054","key":"10.1016\/j.neurot.2025.e00610_bib1","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer's disease: the amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00610_bib2","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer's disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol Med"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00610_bib3","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2174\/1567205014666170417111859","article-title":"Tau in Alzheimer's disease: mechanisms and therapeutic strategies","volume":"15","author":"Gao","year":"2018","journal-title":"Curr Alzheimer Res"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00610_bib4","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s13311-021-01146-y","article-title":"Neuropathology of Alzheimer's disease","volume":"19","author":"Trejo-Lopez","year":"2022","journal-title":"Neurotherapeutics"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00610_bib5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological stageing of Alzheimer-related changes","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00610_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/ph12010041","article-title":"BACE-1 and \u03b3-secretase as therapeutic targets for Alzheimer's disease","volume":"12","author":"Maia","year":"2019","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.neurot.2025.e00610_bib7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1756-6606-4-3","article-title":"APP processing in Alzheimer's disease","volume":"4","author":"Zhang","year":"2011","journal-title":"Mol Brain"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00610_bib8","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1111\/j.1471-4159.2009.05907.x","article-title":"A disintegrin and metalloproteinase (ADAM)-mediated ectodomain shedding of ADAM10","volume":"108","author":"Parkin","year":"2009","journal-title":"J Neurochem"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00610_bib9","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1007\/s00018-019-03404-x","article-title":"Deciphering the neuroprotective and neurogenic potential of soluble amyloid precursor protein alpha (sAPP\u03b1)","volume":"77","author":"Dar","year":"2020","journal-title":"Cell Mol Life Sci"},{"issue":"17","key":"10.1016\/j.neurot.2025.e00610_bib10","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1038\/emboj.2010.167","article-title":"ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons","volume":"29","author":"Kuhn","year":"2010","journal-title":"EMBO J"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00610_bib11","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.jalz.2019.09.075","article-title":"The path forward in Alzheimer's disease therapeutics: reevaluating the amyloid cascade hypothesis","volume":"16","author":"Tolar","year":"2020","journal-title":"Alzheimer's Dement"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00610_bib12","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1038\/nm1295-1291","article-title":"The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathway","volume":"1","author":"Haass","year":"1995","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00610_bib13","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3233\/JAD-130746","article-title":"Presenilin-1 mutations in Alzheimer's disease: an update on genotype-phenotype relationships","volume":"37","author":"Larner","year":"2013","journal-title":"J Alzheimers Dis"},{"issue":"7409","key":"10.1016\/j.neurot.2025.e00610_bib14","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature11283","article-title":"A mutation in APP protects against Alzheimer's disease and age-related cognitive decline","volume":"488","author":"Jonsson","year":"2012","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00610_bib15","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer's disease","volume":"9","author":"Budd","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.neurot.2025.e00610_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.870517","article-title":"Impact of anti-amyloid-\u03b2 monoclonal antibodies on the pathology and clinical profile of Alzheimer's disease: a focus on aducanumab and lecanemab","volume":"14","author":"Shi","year":"2022","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00610_bib17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00610_bib18","article-title":"Donanemab for Alzheimer's disease: a systematic review of clinical trials","volume":"11","author":"Rashad","year":"2022","journal-title":"Healthcare (Basel)"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00610_bib19","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.biopsych.2017.08.010","article-title":"Anti-Amyloid-\u03b2 monoclonal antibodies for Alzheimer's disease: pitfalls and promise","volume":"83","author":"van Dyck","year":"2018","journal-title":"Biol Psychiatry"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00610_bib20","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41582-018-0116-6","article-title":"A critical appraisal of amyloid-\u03b2-targeting therapies for Alzheimer disease","volume":"15","author":"Panza","year":"2019","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00610_bib21","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/med.21622","article-title":"BACE1 inhibitors: current status and future directions in treating Alzheimer's disease","volume":"40","author":"Moussa-Pacha","year":"2020","journal-title":"Med Res Rev"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00610_bib22","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s12031-016-0800-1","article-title":"Functions of the Alzheimer's disease protease BACE1 at the synapse in the central nervous system","volume":"60","author":"Munro","year":"2016","journal-title":"J Mol Neurosci"},{"issue":"18","key":"10.1016\/j.neurot.2025.e00610_bib23","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1706441","article-title":"Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease","volume":"378","author":"Egan","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00610_bib24","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/jnc.12715","article-title":"Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects","volume":"130","author":"Vassar","year":"2014","journal-title":"J Neurochem"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00610_bib25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13024-023-00596-6","article-title":"The Alzheimer's disease-linked protease BACE1 modulates neuronal IL-6 signaling through shedding of the receptor gp130","volume":"18","author":"M\u00fcller","year":"2023","journal-title":"Mol Neurodegener"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00610_bib26","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3233\/JAD-130578","article-title":"A\u03b2PP-selective BACE inhibitors (ASBI): novel class of therapeutic agents for Alzheimer's disease","volume":"37","author":"Descamps","year":"2013","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00610_bib27","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/S0002-9440(10)63419-0","article-title":"Beta-site amyloid precursor protein cleaving enzyme 1 increases amyloid deposition in brain parenchyma but reduces cerebrovascular amyloid angiopathy in aging BACE x APP[V717I] double-transgenic mice","volume":"165","author":"Willem","year":"2004","journal-title":"Am J Pathol"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00610_bib28","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ydbio.2005.05.004","article-title":"Evaluation of the contributions of ADAMs 9, 12, 15, 17, and 19 to heart development and ectodomain shedding of neuregulins beta1 and beta2","volume":"283","author":"Horiuchi","year":"2005","journal-title":"Dev Biol"},{"issue":"40","key":"10.1016\/j.neurot.2025.e00610_bib29","article-title":"Intraneuronal \u03b2-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer disease mutations: potential factors in amyloid plaque formation","volume":"26","author":"Holly","year":"2006","journal-title":"J Neurosci"},{"key":"10.1016\/j.neurot.2025.e00610_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbas.2023.100078","article-title":"The 5XFAD mouse model of Alzheimer's disease displays age-dependent deficits in habituation to a novel environment","volume":"3","author":"Smith","year":"2023","journal-title":"Aging Brain"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00610_bib31","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.bbr.2008.03.035","article-title":"Long-term prevention of Alzheimer's disease-like behavioral deficits in PDAPP mice carrying a mutation in Asp664","volume":"191","author":"Galvan","year":"2008","journal-title":"Behav Brain Res"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00610_bib32","first-page":"335","article-title":"Alternative method of oral dosing for rats","volume":"49","author":"Atcha","year":"2010","journal-title":"J Am Assoc Lab Anim Sci"},{"key":"10.1016\/j.neurot.2025.e00610_bib33","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.brainres.2013.12.029","article-title":"The multi-functional drug tropisetron binds APP and normalizes cognition in a murine Alzheimer's model","volume":"1551","author":"Spilman","year":"2014","journal-title":"Brain Res"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00610_bib34","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/nprot.2006.205","article-title":"Object recognition in rats and mice: a one-trial non-matching-to-sample learning task to study 'recognition memory'","volume":"1","author":"Bevins","year":"2006","journal-title":"Nat Protoc"},{"issue":"18","key":"10.1016\/j.neurot.2025.e00610_bib35","doi-asserted-by":"crossref","first-page":"7130","DOI":"10.1073\/pnas.0509695103","article-title":"Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664","volume":"103","author":"Galvan","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00610_bib36","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.bbr.2009.09.013","article-title":"Reversal of learning deficits in hAPP transgenic mice carrying a mutation at Asp664: a role for early experience","volume":"206","author":"Zhang","year":"2010","journal-title":"Behav Brain Res"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00610_bib37","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1523\/JNEUROSCI.5341-09.2010","article-title":"Many neuronal and behavioral impairments in transgenic mouse models of Alzheimer's disease are independent of caspase cleavage of the amyloid precursor protein","volume":"30","author":"Harris","year":"2010","journal-title":"J Neurosci"},{"issue":"36","key":"10.1016\/j.neurot.2025.e00610_bib38","doi-asserted-by":"crossref","first-page":"26326","DOI":"10.1074\/jbc.M611687200","article-title":"Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice","volume":"282","author":"McConlogue","year":"2007","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00610_bib39","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13195-020-00635-0","article-title":"Partial reduction of amyloid \u03b2 production by \u03b2-secretase inhibitors does not decrease synaptic transmission","volume":"12","author":"Satir","year":"2020","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.neurot.2025.e00610_bib40","first-page":"703","article-title":"The case for low-level inhibiton for the prevention of Alzheimer\u2019s Disease","volume":"17","author":"McDade","year":"2021","journal-title":"Natl Rev"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00610_bib41","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1002\/alz.12164","article-title":"Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease","volume":"16","author":"Wessels","year":"2020","journal-title":"Alzheimer's Dement"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925000881?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925000881?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T07:47:00Z","timestamp":1778831220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747925000881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1878747925000881"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00610","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.08.04.552030","asserted-by":"object"}]},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of an APP-selective BACE1 inhibitor for Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00610","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00610"}}